Analyzing Agenus (AGEN) & Its Competitors

Agenus (NASDAQ: AGEN) is one of 184 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Agenus to similar businesses based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Earnings & Valuation

This table compares Agenus and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Agenus $22.57 million -$126.99 million -3.03
Agenus Competitors $217.29 million -$39.39 million -58.25

Agenus’ peers have higher revenue and earnings than Agenus. Agenus is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Agenus has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Agenus’ peers have a beta of 1.56, suggesting that their average stock price is 56% more volatile than the S&P 500.

Institutional and Insider Ownership

37.9% of Agenus shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 7.9% of Agenus shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Agenus and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agenus 0 1 2 0 2.67
Agenus Competitors 540 2419 6512 127 2.65

Agenus currently has a consensus target price of $6.33, suggesting a potential upside of 77.90%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.96%. Given Agenus’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Agenus is more favorable than its peers.


This table compares Agenus and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agenus -278.76% N/A -65.18%
Agenus Competitors -4,714.38% -582.68% -43.87%


Agenus peers beat Agenus on 7 of the 12 factors compared.

About Agenus

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company’s vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply